Market: NASD |
Currency: USD
Address: Three Columbus Circle
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
📈 Indaptus Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$25.00
-
Upside/Downside from Analyst Target:
240.14%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.035714 |
- |
2025-06-27 |
- |
Stock split |
|
Total Amount for 2025: $0.035714 |
| 2021 |
- |
$0.250000 |
- |
2021-07-27 |
- |
Stock split |
|
Total Amount for 2021: $0.250000 |
| 2020 |
- |
$0.050000 |
- |
2020-10-30 |
- |
Stock split |
|
Total Amount for 2020: $0.050000 |
📅 Earnings & EPS History for Indaptus Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-08-13 | -9.09 |
| 2025-05-14 | -8.96 |
| 2025-03-13 | -10.64 |
| 2024-11-12 | -8.96 |
| 2024-08-12 | -13.16 |
| 2024-05-08 | -12.6 |
| 2024-03-13 | -13.16 |
| 2023-11-06 | -13.16 |
| 2023-08-14 | -10.92 |
| 2023-05-11 | -14.28 |
| 2023-03-17 | -12.32 |
| 2022-11-10 | -11.76 |
| 2022-08-08 | -12.88 |
| 2022-05-12 | -11.48 |
| 2022-03-21 | -6.16 |
| 2021-11-15 | -22.68 |
📰 Related News & Research
No related articles found for "indaptus therapeutics".
